Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with Pseudomonas aeruginosa.

Dings RP, Haseman JR, Leslie DB, Luong M, Dunn DL, Mayo KH.

Biochim Biophys Acta. 2013 Jun;1830(6):3454-7. doi: 10.1016/j.bbagen.2013.02.002. Epub 2013 Feb 9.

2.
3.

Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.

Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, Gentry LO, Garey KW.

Clin Infect Dis. 2008 Mar 15;46(6):862-7. doi: 10.1086/528712.

4.
5.

Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.

Mimoz O, Elhelali N, Léotard S, Jacolot A, Laurent F, Samii K, Petitjean O, Nordmann P.

J Antimicrob Chemother. 1999 Jul;44(1):91-7.

6.

Immunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice.

Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, Hirakata Y, Yamaguchi K.

Antimicrob Agents Chemother. 1997 Feb;41(2):308-13.

7.

Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa.

Yamagishi Y, Terada M, Ohki E, Miura Y, Umemura T, Mikamo H.

J Infect Chemother. 2012 Feb;18(1):127-9. doi: 10.1007/s10156-011-0285-3. Epub 2011 Aug 4.

PMID:
21814800
9.

Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications.

Deslouches B, Islam K, Craigo JK, Paranjape SM, Montelaro RC, Mietzner TA.

Antimicrob Agents Chemother. 2005 Aug;49(8):3208-16.

10.

Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection.

Cirioni O, Silvestri C, Ghiselli R, Orlando F, Riva A, Mocchegiani F, Chiodi L, Castelletti S, Gabrielli E, Saba V, Scalise G, Giacometti A.

J Antimicrob Chemother. 2008 Dec;62(6):1332-8. doi: 10.1093/jac/dkn393. Epub 2008 Sep 16.

12.

The efficacy of piperacillin/tazobactam in experimental Pseudomonas aeruginosa endophthalmitis: a histopathological and microbiological evaluation.

Ozkiris A, Evereklioglu C, Esel D, Akgün H, Göktas S, Erkiliç K.

Curr Eye Res. 2005 Jan;30(1):13-9.

PMID:
15875360
13.
14.

Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?

Tamma PD, Turnbull AE, Milstone AM, Hsu AJ, Carroll KC, Cosgrove SE.

Clin Infect Dis. 2012 Sep;55(6):799-806. doi: 10.1093/cid/cis545. Epub 2012 Jun 13.

15.

In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa.

Yamada K, Yamamoto Y, Yanagihara K, Araki N, Harada Y, Morinaga Y, Izumikawa K, Kakeya H, Hasegawa H, Kohno S, Kamihira S.

J Infect Chemother. 2012 Aug;18(4):472-8. doi: 10.1007/s10156-011-0359-2. Epub 2012 Jan 5.

PMID:
22215228
16.

Shrimp (Penaeus monodon) anti-lipopolysaccharide factor reduces the lethality of Pseudomonas aeruginosa sepsis in mice.

Pan CY, Chao TT, Chen JC, Chen JY, Liu WC, Lin CH, Kuo CM.

Int Immunopharmacol. 2007 May;7(5):687-700. Epub 2007 Feb 7.

PMID:
17386416
18.
19.

PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice.

Song Y, Baer M, Srinivasan R, Lima J, Yarranton G, Bebbington C, Lynch SV.

Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1837-45. doi: 10.1007/s10096-011-1509-2. Epub 2011 Dec 21.

PMID:
22187351
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk